eftilagimod alpha

eftilagimod alpha · Immutep S.A.S.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for eftilagimod alpha, covering 2024-12-17 to 2025-12-11. Get the full timeline:

Most recent: Clinical Trial Update: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC [Phase 2]

See pricing